Skip to content
Abierto
Menu

Award notice, first published as combined synopsis and solicitation

Peramivir (RAPIVAB (peramivir injection)

75A50324Q00006

Office of Assistant Secretary for Preparedness and Response, Aspr/Orm-Sns. Pharmaceutical Preparation Manufacturing.

View on SAM.govMarkdown

Awarded

Biocryst Pharmaceuticals Inc.

$69,388,368.75 on the award notice, September 25, 2024, contract 36F79721D0166

Description

As published on SAM.gov.

This requirement is for the supply of Peramivir (RAPIVAB (peramivir injection) 200mg/20ml vial (10mg/ml inj soln).

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Biocryst Pharmaceuticals Inc.
UEI
MGXADJ6SCLJ5
CAGE
4GBX7
Vendor location
Durham, NC
Contract
75A50324F80012 under 36F79721D0166, delivery order
Obligated
$13,877,673.75, potential $69,388,369
Actions
3 between September 23, 2024 and March 27, 2026
Competition
Full and Open Competition, 1 offer received
Described as
Peramivir (Rapivab 200mg/20ml (10mg/Ml Inj Soln))
Match
solicitation number 75A50324F80012 was reused as the contract number; same awarding office 75A503 (high confidence)
Record
USAspending award page
Recipient
Biocryst Pharmaceuticals Inc.
UEI
MGXADJ6SCLJ5
CAGE
4GBX7
Vendor location
Durham, NC
Contract
36F79721D0166
Obligated
$0.00, potential $1,250,000
Actions
5 between November 21, 2024 and August 31, 2026
Competition
Full and Open Competition, 999 offers received
Set-aside reported
No Set Aside Used.
Described as
Public Law 2025
Match
award number 36F79721D0166 equals the contract number; awarding office not confirmed (medium confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. June 5, 2024

    Combined synopsis and solicitation

    Reusable Insulated Shipping Containers

    Due June 19, 2024 at 4:00 PM EDT. SAM.gov, notice 037eae83d992483f84e91fb04195ace2

  2. September 25, 2024

    Award notice

    Awarded to BIOCRYST PHARMACEUTICALS Inc. Durham for $69,388,369. SAM.gov, notice 5f13e6f45f404995bcc34cf37aac3e08

Points of contact

Also open from this buyer